Hansoh Pharma Discloses Molecular Structures of B7H3 and B7H4 ADCs

▎Armstrong

In July 2025, the molecular structures of Hansoh Pharma's B7H3 ADC and B7H4 ADC new drugs were officially disclosed.

Hansoh Pharma's B7H3 ADC New Drug HS-20093, with the generic name Risvutatug rezetecan, is currently in Phase III clinical trials.

The amino acid sequence of HS-20093 is as follows, and the toxin adopts Hansoh Pharma's SHR-9265 (rezetecan), with a DAR value of 4.

HS-20093 has previously received breakthrough therapy designations for non-small cell lung cancer, small cell lung cancer, and osteosarcoma.

Hansoh Pharma's B7H4 ADC New Drug HS-20089 Has the Generic Name Mocertatug Rezetecan and Is Currently in Phase III Clinical Trials.

The amino acid sequence of HS-20089 is as follows,The toxin uses Hengrui's SHR-9265 (rezetecan), with a DAR value of 4.

HS-20089 previously received breakthrough therapy designation for ovarian cancer.

Summary

Hengrui Medicine and Hansoh Pharma partially share the ADC platform, while adopting differentiated layouts in terms of targets. Hengrui has laid out HER2, Claudin18.2, Nectin-4, Trop2, HER3, CD79b, etc., whereas Hansoh Pharma focuses on B7H3, B7H4, Trop2, EGFR/cMET, etc. The overseas rights of Hansoh Pharma's HS-20089 and HS-20093 have both been licensed to GlaxoSmithKline.